Equity Overview
Price & Market Data
Price: $0.66
Daily Change: +$0.026 / 3.94%
Daily Range: $0.62 - $0.675
Market Cap: $55,400,132
Daily Volume: 208,075
Performance Metrics
1 Week: 20.20%
1 Month: -0.74%
3 Months: -33.54%
6 Months: -17.50%
1 Year: -22.72%
YTD: -5.71%
Company Details
Employees: 18
Sector: Health technology
Industry: Biotechnology
Country:
Details
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.